Daiichi Sankyo - Wikipedia

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in ... DaiichiSankyo FromWikipedia,thefreeencyclopedia Jumptonavigation Jumptosearch Japanesepharmaceuticalcompany DaiichiSankyoCompany,LimitedNativename第一三共株式会社RomanizednameDaiichiSankyōkabushikigaishaTypePublicKKTradedasTYO:4568TOPIXLarge70ComponentTOPIX100ComponentNikkei225ComponentIndustryPharmaceuticalPredecessorsDaiichiPharmaceuticalCompanySankyoCompanyFoundedTokyo,Japan(2005)(bymerger)HeadquartersDaiichiSankyoBuildingA/B3-5-1,Nihonbashi-honcho,Chūō-ku,Tokyo103-8426,JapanKeypeopleSunaoManabe(RepresentativeDirector,andPresident)[1][2]KenKeller(PresidentandCEO,DaiichiSankyo,Inc.)[3]ProductsMedicalequipmentPharmaceuticalproductsVeterinarymedicinesRevenue$9.028billionUSD(FY2019) (¥981.8billionJPY)(FY2019)Netincome$1.276billionUSD(FY2019) (¥138.8billionJPY)(FY2019)Numberofemployees15,348(asofMarch2020)Websitehttp://www.daiichisankyo.comFootnotes /references[4] DaiichiSankyoCompany,Limited(Japanese:第一三共株式会社,Hepburn:DaiichiSankyōKabushiki-gaisha)isaglobalpharmaceuticalcompanyandthesecond-largestpharmaceuticalcompanyinJapan.ItachievedJPY981.8billioninrevenuein2019.ThecompanyownstheAmericanbiotechnologycompanyPlexxikon,AmericanpharmaceuticalcompanyAmericanRegent,GermanbiotechnologycompanyU3Pharma,andrecentlysoldRanbaxyLaboratoriesinIndia.DaiichiSankyoCo.,Ltd.istheproducerofBenicar(Olmesartan),anangiotensinIIreceptorantagonistandtopsellingdrugintheU.S.GlobalsalesofOlmesartanin2013were300.2billionyen. DaiichiSankyo,Inc.(DSI)beganoperatingintheU.S.in2006.ItistheU.S.subsidiaryofDaiichiSankyoCompany,Limited,andamemberoftheDaiichiSankyoGroup.Theorganization,whichincludesU.S.commercialoperationsandglobalclinicaldevelopment(DaiichiSankyoPharmaDevelopment),isheadquarteredinBaskingRidge,NewJersey. DaiichiSankyoEurope,GmbH(DSE),theEuropeansubsidiary,isheadquarteredinMunich,Germany.Theorganizationisresponsiblefordevelopmentandmanufacturingfor12Europeancountries. DaiichiSankyoCompany,LimitedisafullmemberoftheEuropeanFederationofPharmaceuticalIndustriesandAssociations(EFPIA)andoftheInternationalFederationofPharmaceuticalManufacturersandAssociations(IFPMA). Contents 1History 1.1Kickbacks 1.2Acquisitions 2Products 3Pipelinecandidates 4References 5Externallinks History[edit] DaiichiSankyowasestablishedin2005throughthemergerofSankyoCompany,Limited(三共株式会社,SankyōKabushikiKaisha)andDaiichiPharmaceuticalCompany,Limited(第一製薬株式会社,DaiichiSeiyakuKabushikiKaisha),whichwerecentury-oldpharmaceuticalcompaniesbasedinJapan.SankyoCo.,Ltd.wasfoundedbyDr.JokichiTakamine,whopatentedtheisolationofadrenalin.[5][6]TakaminewasalsothefirstpresidentofSankyoCo.,LtdfromMarch1913–July1922.[7]In1990,SankyoacquiredLuitpold-WerkGroup,apharmaceuticalcompanybasedinMunich.[8]In2019,LuitpoldrenameditselfafteritsAmericanRegentbrand.[9]AmericanRegent,nowbasedintheUnitedStates,isasubsidiaryofDaiichiSankyo.[10][11] Kickbacks[edit] Asof2015,DaiichiSankyowasbeing"closelymonitored"aftersettlingchargesconcerningpaymentofremunerationtophysiciansintheformofspeakerfeesaspartofcompany'sPhysicianOrganizationandDiscussionprogram,inviolationoftheFalseClaimsAct,ananti-kickbackstatute.[12] DaiichiSankyoagreedtopaytheUnitedStatesandstateMedicaidprograms$39milliontosettleallegationsbytheUnitedStatesDepartmentofJusticeoverkickbackstodoctors.[12]Aspartofthecompany'sPhysicianOrganizationandDiscussionprogramwhichranfrom2005through2011,DaiichiSankyopaidphysiciansimproperkickbacksintheformofspeakerfeestoinducephysicianstoprescribeDaiichiSankyo'sdrugs,includingAzor,Benicar,TribenzorandWelchol.[12]Allegedly,paymentsweremadetophysiciansevenwhenphysicianparticipantsinPODstookturns“speaking”onduplicativetopicsoverDaiichi-paiddinners,therecipientspokeonlytomembersofhisorherownstaffinhisorherownoffice,ortheassociateddinnerwassolavishthatitscostexceededDaiichiSankyo'sowninternalcostlimitationof$140perperson.[12] “Schemessuchasthisareparticularlyabhorrent,”saidInspectorGeneralDanielR.LevinsonfortheU.S.DepartmentofHealthandHumanServices.[12]“ManufacturersandphysicianswhoengageinthemarecheatingMedicareandMedicaidoutofmillionsofdollarsandthreateningprogramsuponwhichmanyelderlyanddisabledAmericansrely.Myofficewilltakewhateverstepsnecessarytoguardagainstimproperalliancesbetweenmanufacturersofdrugsandthosewhoprescribethem.ThroughourcorporateintegrityagreementwewillbecloselymonitoringDaiichiSankyo.”[12] Acquisitions[edit] In2006,DaiichiSankyoacquiredZepharma,theOTCdrugsunitofAstellasPharma.OnJune10,2008,thecompanyagreedtotakeamajority(64%)stakeinIndiangenericdrugmakerRanbaxy,withadealvaluedatabout$4.6billion.[13][14] ItacquiredU3PharmainJune2008,contributingatherapeuticanti-HER3antibodytothecompany'santicancerportfolio.[15]ThecompanyclosedU3Pharmain2015.[16] TheacquisitionofPlexxikon,aBerkeley,California-basedpharmaceuticalstart-upcompany,wascompletedonApril4,2011for$805millionandanadditional$130millioninmilestonepayments,pendingonthesuccessofVemurafenib(Plexxikon'sleadprogram)anoral,noveldrugthattargetstheoncogenicBRAFmutationpresentinabouthalfofmelanomacancersandabouteightpercentofallsolidtumors.DaiichiSankyoisretainingUSco-promotionrightofthe(Rochelicensed)drug.[17] OnApril7,2014,DaiichiSankyoannouncedithadagreedtovoteitssharesinRanbaxyinfavorofSunPharma'sacquisitionof100%ofRanbaxythroughthemergerprocesswhichentailedashareswap.ThetransactionissettocloseinDecember2014,pendingshareholder,courtandregulatoryapprovalsandothercustomaryconditions.OnSeptember29,2014,DaiichiSankyoagreedtoacquireAmbitBiosciencesforapproximately$410million,thedealenabledDaiichitogainthePhaseIIIcancercompoundquizartinib.[18]OnApril20,2015,thecompanyannouncedithadsoldoffthe8.9%stakeinSunPharmaceuticalIndustriesitacquiredwhenacquiringRanbaxy,raising$3.2billion.[19] Ittransferred41ofitsproductsinJapantoAlfresaHoldingsCorporationforJPY4.2billionin2018inordertofocusononcology.[20]Thecompanyacquiredramosetron,nicardipineandbarnidipinefromAstellasPharmainOctober2019.[21] InJanuary2020,thecompany'smarketvalueroseaboveJPY5trillionaftertheU.S.FoodandDrugAdministrationapprovalandreleaseofEnhertu,[22]anantibody-drugconjugateforcancertreatment.[23]DaiichiSankyodevelopedEnhertuincooperationwithAstraZeneca,[22]whichagreedinMarch2019topayupto$6.9billiontoDaiichiSankyoinexchangeforashareofEnhertu'ssales.[24][25]TheshutdownofPlexxikonwasannouncedin2022[26]asDaiichiSankyopivotstofocusonmoreantibody-drugconjugatetherapies.[27] Thefollowingisanillustrationofthecompany'smajormergersandacquisitionsandhistoricalpredecessors(thisisnotacomprehensivelist): DaiichiSankyo         Daiichi Sankyo   SankyoCompany,Limited     DaiichiPharmaceuticalCompany,Limited       Zepharma(Acq2006)         RanbaxyLaboratories(Acq2008)           U3Pharma(Acq2008)           Plexxikon(Acq2011)           AmbitBiosciences(Acq2014)       Products[edit] Thislistisnotcomprehensive.[28] Oncology Enhertu(trastuzumabderuxtecan,fam-trastuzumabderuxtecan-nxkiintheUnitedStatesonly)[29] Turalio(pexidartinib)[30][31] Vanflyta(quizartinib)(availableonlyinJapan)[32] Zelboraf(vemurafenib)[33][34] Cardiovascular Benicar(olmesartanmedoxomil)(alsosoldasBenicarHCT,Azor,Olmetec,Rezaltas,Sevikar,andTribenzor)[35] Effient(prasugrel)(co-marketedwithEliLillyandCompany;alsosoldasEfient)[36] Lixiana/Savaysa(edoxaban)[37][38] Minnebro(esaxerenone)(availableonlyinJapan)[39] Nilemdo(bempedoicacid,onlysoldintheEU)(alsosoldasNustendi)[40] Other Canalia(teneligliptin,canagliflozin)(availableonlyinJapan)[41] Evoxac(cevimelinehydrochloride)[42] Injectafer(ferriccarboxymaltoseinjection)[43] Memary(memantinehydrochloride)(availableonlyinJapan)[44] Nexium(esomeprazole)(onlyinJapan;marketedbyAstraZenecaelsewhere)[45] Pralia(denosumab)[46](onlyavailableinJapan;alsosoldthereasRanmark)[47] Tarlige(mirogabalin)(onlyavailableinJapan)[48] Tenelia(teneligliptinhydrobromidehydrate)[49] Venofer(ironsucrose)[50] Vimpat(lacosamide)(onlyavailableinJapan;co-marketedwithUCB)[51] Welchol(colesevelamHCl)[52] Pipelinecandidates[edit] Selectmid-stageandlate-stageinvestigationalcandidatesinDaiichi-Sankyo'spipelineinclude: Datopotamabderuxtecan(Dato-DXd)[53][54] Patritumabderuxtecan(HER3-DXd)[55][56] VN-0102[57] Valemetostat[58] DS-1647[59] References[edit] ^"DaiichiSankyonamecurrentCOOSunaoManabeasfirm'snewCEO".Pharmafile.4December2019.Retrieved12November2020. ^"MessagefromOurCEO".DaiichiSankyo.Retrieved12November2020. ^"CorporateManagementInformation–KenKeller".DaiichiSankyo,Inc.Retrieved30November2020. ^"ValueReport2020"(PDF).DaiichiSankyoGroup.31March2020.p. 45.Retrieved30November2020. ^Bennett,Joan."TheTimeLine:Adrenalinandcherrytrees".pubs.acs.org.Retrieved24January2016. ^Kawakami,K.K.(1928).JokichiTakamine:ARecordofhisAmericanAchievements.NewYork:WilliamEdwinRudge. ^"13thTakamineMemorialDaiichiSankyoPrizeWinnerAnnounced-Media&Investors-DaiichiSankyo".www.daiichisankyo.com.Retrieved24January2016. ^"SankyoBuysDrugMaker".TheNewYorkTimes.19January1990.Retrieved17December2020. ^"LuitpoldPharmaceuticalsRenamedAmericanRegent".AmericanPharmaceuticalReview.2January2019.Retrieved17December2020. ^"DaiichiSankyocreatesnewbizunitforoncology".BioSpectrumAsia.13November2020.Retrieved17December2020. ^"LeadershipTransitionsUpcomingatDaiichiSankyo,AmericanRegent".PharmaLive.7December2020.Retrieved17December2020. ^abcdef"DaiichiSankyoInc.AgreestoPay$39MilliontoSettleKickbackAllegationsUndertheFalseClaimsAct".OfficeofPublicAffairs.U.S.DepartmentofJustice.2015-01-09.Retrieved2016-04-06.Thisarticleincorporatestextfromthissource,whichisinthepublicdomain. ^"Ranbaxy-Daiichimarriage:ImplicationsforIndianpharma".June11,2008.RetrievedApril29,2014. ^"RanbaxypromoterstosellstaketoJapan'sDaiichi".June11,2008.RetrievedApril29,2014. ^"DaiichiSankyoIntendstoPurchaseU3PharmaforRoughly$236M".GeneticEngineering&BiotechnologyNews.MaryAnnLiebert,Inc.May21,2008.RetrievedJuly6,2008. ^White,Victoria(1December2015)."DaiichiSankyotocloseresearchsubsidiaryU3Pharma".DrugTargetReview.Archivedfromtheoriginalon2021-05-20.Retrieved1December2020. ^"DaiichiSankyoToAcquirePlexxikon".Plexxikon.February28,2011.Archivedfromtheoriginalon2011-03-06.RetrievedApril29,2014. ^"GEN-NewsHighlights:DaiichiSankyotoAcquireAmbitBiosciencesforUpto$410M".GEN.2014-09-29. ^"GEN-NewsHighlights:DaiichiSankyoSellsOffStakeinSunPharma".GEN.2015-04-21. ^"DaiichiSankyosplitstooffloadoldassetsandfocusononcologyambition".ThePharmaLetter.1August2018.Retrieved1December2020. ^"DaiichiSankyobuysthreedrugstoboostpresenceinAsia".ThePharmaLetter.15October2019.Retrieved1December2020. ^abTakada,Noriyuki;Kawana,Yukihiro;Sakabe,Yoshinaru(28January2020)."DaiichiSankyoharnesses'old'R&Dtostrikecancerdruggold".NikkeiAsia.Retrieved1December2020. ^Matsuyama,Kanoko(16June2019)."Drugdevisedtoreplacechemotherapymayreshapecancercare".TheJapanTimes.Retrieved1December2020. ^Terry,Mark(29March2019)."AstraZenecaandDaiichiSankyoSign$6.9BillionDealforaSingleCancerDrug".BioSpace.Retrieved1December2020. ^Tatelbaum,Julianna(29March2019)."GlobalpharmagiantAstraZenecastrikes$6.9billiondealtoexpandcancerportfolio".CNBC.Retrieved1December2020. ^Wells,Madeline(2022-01-12)."SouthSFcompanyboughtfor$800millionisbeingshutdown".SFGATE.Archivedfromtheoriginalon2022-01-12. ^Taylor,NickP.(2022-01-12)."Daiichiaxes60-personPlexxikonR&DfacilityinCaliforniatofreeupcashforADCdevelopment".FierceBiotech.Archivedfromtheoriginalon2022-01-12. ^"Products-DaiichiSankyo".DaiichiSankyo.RetrievedJune15,2021. ^"AZ,DaiichiSankyogetearlyokayforDS-8201,nownamedEnhertu".PMLive.23December2019.Retrieved3December2020. ^Taylor,Phil(5August2019)."DaiichiSankyo'spexidartinibisfirstFDA-approveddrugforraretumour".PharmaPhorum.Retrieved3December2020. ^"FDAapprovesTuralio,thefirsttherapyforrarejointtumor".ThePharmaLetter.3August2019.Retrieved3December2020. ^Idrus,AmirahAl(21June2019)."FDAnixesDaiichi'sbloodcancerdrugquizartinibafterJapaneseregulatorswaveitthrough".FierceBiotech.Retrieved3December2020. ^"First-in-classskincancerdrugapproved".PMLive.18August2011.Retrieved13May2021. ^"Products".DaiichiSankyo.Retrieved2December2020. ^Elvidge,Suzanne(2August2017)."Daiichispends$300MtosettleBenicarsuits".BioPharmaDive.Retrieved3December2020. ^"DaiichiSankyosaysprasugrelhitsgoalsinthromboticstrokestudy".ThePharmaLetter.21July2020.Retrieved3December2020. ^Weinberg,Ido(9January2015)."FDAapprovesedoxabantoreducestrokerisk,treatDVTandPE".Healio.Retrieved3December2020. ^"FDAapprovesDaiichiSankyobloodthinnerSavaysa".PharmaTimes.9January2015.Retrieved3December2020. ^Terry,Mark(8November2019)."DaiichiSankyo'sHypertensionDrugHitsMarkinDiabeticNephropathyTrial".BioSpace.Retrieved3December2020. ^"ECnodforDaiichiSankyo'scholesterollowerersNilemdoandNustendi".ThePharmaLetter.6April2020.Retrieved13May2021. ^"Newcombinationtherapyfortype2diabetesapprovedinJapan".ThePharmaLetter.3July2017.Retrieved3December2020. ^Dey,Sushmi(9October2012)."RanbaxylaunchesauthorisedgenericofDaiichi'sEvoxacinUS".BusinessStandardIndia.Retrieved13May2021. ^Steinberg,Julie(29July2020)."DaiichiSankyoStillFacesClaimsOverInjectableAnemiaDrug".BloombergLaw.Retrieved3December2020. ^"DaiichiSankyoLookingtoEstablish"BaseTreatment"PositionforMemary".PharmaJapan.23April2012.Retrieved3December2020. ^"AZpockets$100millioninDaiichiSankyodealforNexium".PharmaTimes.29October2010.Retrieved3December2020. ^"DaiichiSankyofilesRanmarktotreatgiantcelltumorofboneinJapan".ThePharmaLetter.29August2013.Retrieved3December2020. ^"DaiichiSankyodebutsbonecancerdrugRanmarkinJapan".ThePharmaLetter.17April2012.Retrieved3December2020. ^"DaiichiSankyowinsapprovaltocompetewithLyricainJapan".ThePharmaLetter.9January2019.Retrieved3December2020. ^Haneda,Masakazu;Kadowaki,Takashi;Ito,Hiroshi;Sasaki,Kazuyo;Hiraie,Sonoe;Ishii,Manabu;Matsukawa,Miyuki;Ueno,Makoto(2018)."SafetyandEfficacyofTeneligliptininPatientswithType2DiabetesMellitusandImpairedRenalFunction:InterimReportfromPost-marketingSurveillance".DiabetesTherapy.9(3):1083–1097.doi:10.1007/s13300-018-0416-2.PMC 5984919.PMID 29637459. ^Bulik,BethSnyder(1April2018)."DaiichiSankyopartnerswithCrohn's&ColitisFoundationtodrawattentiontoirondeficiency".FiercePharma.Retrieved3December2020. ^"UCBandDaiichiSankyo'sVimpatapprovedinJapan".ThePharmaLetter.4July2016.Retrieved3December2020. ^"DaiichiSankyosaysFDAOKsWelcholfordiabetestreatment".Reuters.18January2008.Retrieved3December2020. ^"Datopotamabderuxtecan–DS-1062(TROP2ADC)".ADCReview.Retrieved17December2020. ^Hergert,Jessica(31January2021)."Relapsed/RefractoryMetastaticNSCLCTumorsRespondtoDatopotamabDeruxtecaninEarlyTrial".CancerNetwork.Retrieved13May2021. ^"PatritumabDeruxtecan–U3-1402–HER3ADC".ADCReview.Retrieved17December2020. ^Seymour,Caroline(30January2021)."PatritumabDeruxtecanShowsEarlyActivityinMetastaticEGFR-MutantNSCLC".TargetedOncology.Retrieved13May2021. ^"DaiichiSankyosetsoutplansfordissolutionofJapanVaccine".ThePharmaLetter.26December2018.Retrieved3December2020. ^"DaiichiSankyosetsupcollaborationsforvalemetostatinB-celllymph".ThePharmaLetter.25February2021.Retrieved13May2021. ^"DaiichiSankyo'sOncolyticVirusGetsOrphanStatus".PharmaJapan.12July2017.Retrieved17December2020. DaiichiSankyoAnnualReport2008 Externallinks[edit] Japanportal Medicineportal Tokyoportal Companiesportal DaiichiSankyo(inEnglish) "Companyhistorybooks(Shashi)".ShashiInterestGroup.April2016.WikicollectionofbibliographicworksonDaiichiSankyo vteTOPIX100companiesofJapanCore30 Astellas Daikin FANUC Hitachi Honda JREast JT KDDI MitsubishiCorporation MitsubishiEstate Mitsui&Co MitsuiFudosan Mizuho MUFG Murata Nintendo Nomura NTT NTTDocomo Recruit Seven&i Shin-Etsu SMC SoftBank Sony SumitomoMitsuiFinancial Takeda TokyoElectron TokioMarine Toyota Large70 ÆON Ajinomoto ANA AsahiBreweries AsahiKasei BandaiNamcoHoldings Bridgestone Canon ChubuElectricPower ConcordiaFinancial Dai-ichiLife DaiichiSankyo DaitoTrustConstruction DaiwaHouse DaiwaSecurities Denso Eisai FastRetailing EneosHoldings Fujifilm Fujitsu Hoya Inpex Isuzu Itochu JapanAirlines JRCentral JRWest JFE Kao KEPCO Keyence Kirin Komatsu Kubota Kyocera Marubeni Mazda MitsubishiChemical MitsubishiElectric MitsubishiHeavyIndustries MS&AD Nidec NipponSteel Nissan NittoDenko OnoPharmaceutical OrientalLand Orix OsakaGas OtsukaPharmaceutical Panasonic Rakuten Resona Secom SekisuiHouse Shionogi Shiseido SompoHoldings Subaru SumitomoCorporation SumitomoElectric SumitomoMetalMining SumitomoChemical SumitomoMitsuiTrust SumitomoRealty Suzuki T&DHoldings Toray Toshiba Unicharm YamatoTransport vteNikkei225companiesofJapan 7&i Advantest ÆON AGC Ajinomoto Alps ANA Amada AozoraBank AsahiBreweries AsahiKasei Astellas BandaiNamcoHoldings Bridgestone Canon Casio ChibaBank Chiyoda Chuden Chugai CitizenHoldings Comsys ConcordiaFinancial CreditSaison Dai-ichiLife DaiichiSankyo Daikin DainipponSumitomoPharma DaiwaHouse DaiwaSecurities Denka Denso Dentsu DNP Dowa Ebara Eisai Eneos Fanuc FastRetailing FujiElectric Fujifilm Fujikura Fujitsu FukuokaFinancial FurukawaGroup FurukawaElectric GSYuasa HeiwaRealEstate Hino Hitachi HitachiConstructionMachinery Hitz HokuetsuPaper Honda IHI INPEX Isetan-Mitsukoshi Isuzu Itochu JFE J.FrontRetailing JGC JRCentral JREast JRWest JSW JT JTEKT Kajima KEPCO Kao Kawasaki KDDI Keio Keisei Keyence Kikkoman Kirin KLine Kobelco Komatsu Konami KonicaMinolta Kubota Kuraray Kyocera KyowaHakkoKirin Marubeni MaruhaNichiro Marui MatsuiSecurities Mazda Meidensha MeijiHoldings MES Minebea MitsubishiChemical MitsubishiCorporation MitsubishiElectric MitsubishiEstate MitsubishiHeavyIndustries MitsubishiLogistics MitsubishiMaterials MitsubishiMotors Mitsui&Co MitsuiChemicals MitsuiFudosan MitsuiKinzoku MitsumiElectric Mizuho MOL MS&AD MUFG MurataManufacturing NEC Nexon NEG NGK Nichirei Nikon Nintendo NipponExpress NipponKayaku NipponLightMetal NipponHam NipponPaperIndustries NipponSoda NipponSuisan NissanMotorCompany NissanChemical NisshinSeifun NisshinSteel Nittobo NittoDenko SompoJapanNipponkoaHoldings Nomura NSG NSK NSSMC NTN NTT NTTData NYK Obayashi Odakyu OjiHoldingsCorporation OKI Okuma Olympus OsakaGas PacificMetals Panasonic Pioneer Resona Ricoh SapporoHoldings SCREEN Secom SekisuiHouse Sharp Shimz Shin-Etsu ShinseiBank Shionogi Shiseido ShizuokaBank ShowaDenko ShowaShell SoftBank Sojitz Sony SubaruCorporation SUMCO SumitomoChemical SumitomoCorporation SumitomoElectric SumitomoHeavyIndustries SumitomoMetalMining SumitomoMitsuiFinancial SumitomoMitsuiTrust SumitomoOsakaCement SumitomoRealty Suzuki T&D TaiheiyoCement Taisei TaiyoYuden Takara Takashimaya Takeda TDK Teijin TEPCO Terumo Tobu Toho TohoZinc TokaiCarbon TokuyamaCorporation TokioMarine TokyoDome TokyoElectron TokyoGas TokyoTatemono Tokyu TokyuLand Toppan Toray Toshiba Tosoh Toto Toyobo Toyota ToyotaTsusho TrendMicro UBE Unitika Uny Yahoo!Japan Yamaha YamatoTransport Yasakawa YokogawaElectric YokohamaRubber AuthoritycontrolGeneral ISNI 1 VIAF 1 WorldCat Nationallibraries Japan Retrievedfrom"https://en.wikipedia.org/w/index.php?title=Daiichi_Sankyo&oldid=1093024976" Categories:TOPIX100DaiichiSankyoPharmaceuticalcompaniesbasedinTokyoVeterinarymedicinecompaniesCompanieslistedontheTokyoStockExchangeCompanieslistedontheOsakaExchangeCompanieslistedontheNagoyaStockExchangePharmaceuticalcompaniesestablishedin2005PharmaceuticalcompaniesofJapanCompaniesformerlylistedontheNasdaqMultinationalcompaniesheadquarteredinJapanJapanesebrandsJapanesecompaniesestablishedin2005PharmaceuticalcompaniesbasedinNewJerseyCOVID-19vaccineproducersHiddencategories:SourceattributionArticleswithshortdescriptionShortdescriptionmatchesWikidataArticlescontainingJapanese-languagetextArticleswithISNIidentifiersArticleswithVIAFidentifiersArticleswithWORLDCATIDidentifiersArticleswithNDLidentifiers Navigationmenu Personaltools NotloggedinTalkContributionsCreateaccountLogin Namespaces ArticleTalk English Views ReadEditViewhistory More Search Navigation MainpageContentsCurrenteventsRandomarticleAboutWikipediaContactusDonate Contribute HelpLearntoeditCommunityportalRecentchangesUploadfile Tools WhatlinkshereRelatedchangesUploadfileSpecialpagesPermanentlinkPageinformationCitethispageWikidataitem Print/export DownloadasPDFPrintableversion Inotherprojects WikimediaCommons Languages العربيةتۆرکجهDeutschفارسیFrançais한국어BahasaIndonesiaItalianoBahasaMelayu日本語PortuguêsРусскийSuomiSvenska中文 Editlinks